Trial Profile
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs CV 301 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms MAGNI-lung-01
- Sponsors Bavarian Nordic
- 20 Dec 2022 Results assessing safety and tolerability published in the International Journal of Cancer
- 26 Feb 2020 Status changed from active, no longer recruiting to completed.
- 20 May 2019 Results published in the Clinical Cancer Research